CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 198-202

  Manzke, Oliver ^a   Titzer, Sandra ^a   Tesch, Hans ^a   Diehl, Volker ^a   Bohlen, Heribert ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

CD28; CD3 x CD19 bispecific antibodies; Locoregional treatment; Non Hodgkin's lymphoma

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CASE REPORT; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD28; ANTIGENS, CD3; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; MIDDLE AGED;

EID: 0030856803     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050432     Document Type: Article

References (27)

1. Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM (1992) G19.4(alpha CD3) × B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4; 11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80:2826
2. Azuma M, Phillips JH, Lanier LL (1992) CD28 co-stimulation of T-cell-mediated cytotoxicity. Int J Cancer Suppl 7:33
3. Azuma M, Cayabyab M, Phillips JH, Lanier LL (1993) Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol 150:2091
4. Azuma A, Yagita H, Okumura K, Kudoh S, Niitani H (1994) Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 × anti-(tumour-associated antigen) bispecific antibody. Cancer Immunol Immunother 38:294
5. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H (1993) Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803
6. Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H (1997) Prevention of Epstein-Barr virus-induced human B cell lymphoma in severe combined immunodeficient mice treated with CD3 × CD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Cancer Res 57:1704
7. Bolhuis RL, Sturm E, Braakman E (1991) T cell targeting in cancer therapy. Cancer Immunol Immunother 34:1
8. Canevari S, Menard S, Mezzanzanica D, Miotti S, Pupa SM, Lanzavecchia A, Colnaghi MI (1988) Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumour cell lysis by cytotoxic T cells . Int J Cancer [Suppl] 2:18
9. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, Banchereau J (1994) B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 180:1841
10. Demanet C, Brissinck J, De Jonge J, Thielemans K (1995) In vivo studies using bispecific antibodies (anti-CD3 × anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. J Hematother 4:363
11. Ferrini S, Cambiaggi A, Sforzini S, Marciano S, Canevari S, Mezzanzanica D, Colnaghi MI, Grossi CE, Moretta L (1993) Targeting of T lymphocytes against EGF-receptor+ tumour cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T cell activiation. Int J Cancer 55:931
12. Haagen IA (1995) Performance of CD3 × CD19 bispecific monoclonal antibodies in B cell malignancy. Leuk Lymphoma 19:381
13. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607
14. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ (1994) Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180:631
15. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J. Kapp U, Diehl V, Pfreundschuh M (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830
16. Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH. Berendsen HH, Limburg PC, The TH, de Leij L, (1993) Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 37:400
17. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf W, The TH, de Leij L, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70:652
18. Luna-Fineman S, Lee JE, Wesley PK, Clayberger C, Krensky AM (1992) Human cytotoxic T lymphocytes specific for autologous follicular lymphoma recognize immunoglobulin in a major histocompatibility complex restricted fashion. Cancer 70:2181
19. Manzke O, Tesch H, Diehl V, Bohlen H (1997) Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic introduction chromatography. Journal of Immunological Methods (in press)
20. Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537
21. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368
22. Nossal GJ (1993) Tolerance and ways to break it. Ann N Y Acad Sci 690:34
23. Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H (1991) Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab′ antibody cross-linked to anti-CD10 Fab′ antibody. Blood 77:1044
24. van Dijk J, Warnaar SO, van Eendenburg J, van DJ, Warnaar SO, van EJ, Thienpont M, Braakman E, Boot JH, Fleuren GJ, Bolhuis RL (1989) Induction of tumour-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43:344
25. Weiner GJ, De Gast GC (1995) Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma 16:199
26. Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL (1989) Characterization of the CD4+ and CD8+ tumour-infiltratin lymphocytes propagated with bispecific monoclonal antibodies. J Immunol 143:3404
27. Yssel H, Spits H, De Vries J (1984) A cloned T cell line cytotoxic for autologous and allogeneic B lymphoma cells. J Exp Med 160:239